UPB
Upstream Bio, Inc. NASDAQ Listed Oct 11, 2024$6.30
Pre-mkt
$6.25
-0.79%
Mkt Cap $339.3M
52w Low $5.92
1.4% of range
52w High $32.60
50d MA $8.43
200d MA $17.52
P/E (TTM)
—
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.0x
ROE
-42.2%
P/FCF
-2.5x
RSI (14)
27.60
ATR (14)
$0.47
Beta
1.83
50d MA
$8.43
200d MA
$17.52
Avg Volume
658.5K
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
890 Winter Street · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.79 | -0.75 | +5.1% | 8.95 | +0.1% | +4.6% | -6.1% | +3.4% | -6.4% | -5.6% | — |
| May 11, 2026 | BMO | — | — | — | 9.09 | +1.2% | +0.2% | -1.8% | +4.6% | -6.1% | +3.4% | — |
| May 8, 2026 | BMO | — | — | — | 8.99 | -1.2% | +1.1% | +0.2% | -1.8% | +4.6% | -6.1% | — |
| May 7, 2026 | BMO | — | — | — | 9.19 | -0.5% | -2.2% | +1.1% | +0.2% | -1.8% | +4.6% | — |
| Mar 26, 2026 | BMO | -0.73 | -0.79 | -8.2% | 9.79 | -10.9% | -11.4% | +0.0% | +1.3% | +2.5% | +3.4% | — |
| Nov 5, 2025 | BMO | -0.78 | -0.63 | +19.2% | 23.97 | +0.1% | -1.3% | +0.0% | -3.0% | +2.4% | +1.2% | — |
| Aug 6, 2025 | BMO | -0.61 | -0.74 | -21.3% | 16.72 | +2.0% | -5.3% | +0.0% | +1.0% | +3.7% | +5.5% | — |
| May 6, 2025 | BMO | -0.49 | -0.51 | -4.1% | 8.21 | -0.7% | +4.5% | +0.0% | +3.0% | -0.2% | +7.7% | — |
| Mar 13, 2025 | BMO | -0.56 | -1.59 | -183.9% | 9.06 | +3.0% | +6.1% | +0.0% | +2.7% | -8.4% | -5.4% | — |
| Nov 7, 2024 | BMO | -0.54 | -6.96 | -1200.3% | 27.02 | +1.5% | -3.1% | +0.0% | +2.4% | -1.6% | -1.8% | — |
| Dec 31, 2023 | BMO | — | -0.14 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | BMO | — | -0.09 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 | JP Morgan | Downgrade | Overweight → Neutral | $8 | $6.38 | $6.03 | -5.5% | -4.4% | +0.0% | -3.0% | +3.9% | +1.6% |
| Jun 3 | H.C. Wainwright | Initiates | Buy | $36 | $7.25 | $7.52 | +3.7% | +5.2% | -2.6% | -5.1% | -8.5% | +3.7% |
| Mar 27 | Evercore ISI | Downgrade | Outperform → In Line | — | $9.79 | $8.72 | -10.9% | -11.4% | +1.3% | +2.5% | +3.4% | +2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Ambrose Allison | General Counsel | Sell | 477 | $6.10 | $3K | 16,048 | +1.63% | — |
| Jun 16, 2026 | Deykin Aaron | Chief Medical Officer | Sell | 895 | $6.10 | $5K | 33,197 | +1.63% | — |
| Jun 16, 2026 | Houghton Adam | Chief Business Officer | Sell | 700 | $6.10 | $4K | 23,601 | +1.63% | — |
| Jun 16, 2026 | Sutherland Everett Rand | Chief Executive Officer | Sell | 2,095 | $6.10 | $13K | 70,812 | +1.63% | — |
| Jun 16, 2026 | GRAY MICHAEL | CFO and COO | Sell | 853 | $6.10 | $5K | 28,795 | +1.63% | — |
8-K
Upstream Bio, Inc. -- 8-K Filing
Jun 10
8-K · 2.02
!! High
Upstream Bio, Inc. -- 8-K 2.02: Earnings Results
May 13
8-K
Unknown — 8-K Filing
Universal Proptech's at-the-market offering provides flexible capital-raising ability without immediate dilution, though investors should monitor for potential future share dilution if the company exercises this option.
Mar 26
8-K
Unknown — 8-K Filing
UPB's advancement to Phase 3 testing for verekitug signals potential commercialization progress, but investors should recognize clinical-stage companies carry high failure risk despite promising development milestones.
Mar 26
8-K · 7.01
! Medium
Upstream Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Upstream Bio presented Phase 2 VALIANT trial data for verekitug in severe asthma, disclosing preliminary efficacy results that will likely influence investor sentiment toward the clinical program's viability and commercial potential.
Feb 11
8-K · 7.01
! Medium
Upstream Bio, Inc. -- 8-K 7.01: Regulation FD Disclosure
Upstream Bio disclosed material information via press release that investors should review in the exhibit for updates on company developments or business operations.
Feb 11
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 16
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | BlackRock Health Sciences Opportunities Portfolio | 341,675 | $3M | Feb 2026 |
| 2 | Direxion Daily S&P Biotech Bull 3X Shares | 25,665 | $798K | Jan 2026 |
| 3 | Avantis U.S. Small Cap Equity ETF | 80,783 | $620K | Feb 2026 |
| 4 | Virtus LifeSci Biotech Clinical Trials ETF | 10,379 | $323K | Jan 2026 |
| 5 | Small Cap Index Fund | 13,807 | $124K | Mar 2026 |
| 6 | Adara Smaller Companies Fund | 5,900 | $45K | Feb 2026 |
| 7 | Avantis U.S. Small Cap Equity Fund | 5,295 | $41K | Feb 2026 |
| 8 | Avantis U.S. Equity ETF | 4,515 | $35K | Feb 2026 |
| 9 | Innovator U.S. Small Cap Managed Floor ETF | 864 | $27K | Jan 2026 |
| 10 | Pacer WealthShield ETF | 503 | $16K | Jan 2026 |
| 11 | Penn Series Small Cap Index Fund | 900 | $8K | Mar 2026 |
| 12 | Avantis Total Equity Markets ETF | 937 | $7K | Feb 2026 |
| 13 | Gabelli Healthcare & WellnessRx Trust | 400 | $4K | Mar 2026 |
| 14 | Russell 2000 Fund | 76 | $684 | Mar 2026 |
| 15 | Russell 2000 1.5x Strategy Fund | 46 | $414 | Mar 2026 |
| 16 | Avantis Responsible U.S. Equity ETF | 34 | $261 | Feb 2026 |
Valuation
Market Cap
$339.3M
Enterprise Value
-$1.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.13x
P/B
1.00x
P/S
102.13x
P/FCF
-2.55x
EV/EBITDA
—
Shares Out
53.9M
Financials (TTM)
Revenue
$3.3M
Net Income
-$156.8M
EBITDA
-$156.6M
Free Cash Flow
-$133.3M
Op Cash Flow
-$133.3M
EPS Basic
$-2.66
EPS Diluted
$-2.91
EPS Forward
$-2.89
Gross Margin
98.5%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$353.8M
Total Liab.
$14.0M
Total Equity
$339.8M
Cash
$341.5M
LT Debt
$549K
Book Value/Sh
$6.31
Debt/Equity
0.00x
Current Ratio
26.15
Quick Ratio
26.15
Returns & Growth
ROE
-42.2%
ROA
-40.6%
ROIC
-47.0%
Rev Growth YoY
+20.4%
EPS Growth YoY
-78.5%
Price Returns
2W
-4.9%
1M
-8.9%
3M
+8.9%
6M
-70.8%
12M
-9.4%
Technicals
52W High
$32.60
52W Low
$5.92
50d MA
$8.43
200d MA
$17.52
RSI (14)
27.60
ATR (14)
$0.47
Beta
1.83
Avg Volume
658K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$33.00
High
$51.00
Low
$15.00
Median
$33.00
Data updated apr 27, 2026 6:54am
· Source: financialmodelingprep.com